Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 887 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Radiotherapy followed by chemotherapy Clear all
Terminated Not applicable Interventional Results available

Blue and Amber Light Exposure in Patients With Rectal and Pancreatic Cancer

NCT06164691
View directory record Official record
Conditions
Pancreatic Neoplasms, Rectal Neoplasms
Interventions
Blue light, Amber light, Ambient White Light
Device · Other
Lead sponsor
Matthew Neal MD
Other
Eligibility
19 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 15, 2026, 1:05 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)

NCT00096460
View directory record Official record
Conditions
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Follicular Lymphoma
Interventions
Cyclophosphamide and Rituximab, Filgrastim, Chemotherapy or Radiation therapy, Non-myeloablative Conditioning regimen, Allogeneic transplant, Autologous transplant, Rituximab maintenance therapy, GVHD Prophylaxis
Drug · Radiation · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
30
States / cities
Duarte, California • La Jolla, California • Stanford, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Oct 15, 2026, 1:05 AM EDT
Completed Phase 2 Interventional Results available

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

NCT00482391
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, paclitaxel, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 15, 2026, 1:05 AM EDT
Completed Phase 2 Interventional Results available

Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar

NCT00869258
View directory record Official record
Conditions
Pancreatic Cancer Stage IVA
Interventions
Gemcitabine, docetaxel, and capecitabine, Radiation therapy with gemzar
Drug · Radiation
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Oct 15, 2026, 1:05 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer

NCT01959672
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions
4-Dimensional Computed Tomography, Fluorouracil, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Nelfinavir Mesylate, Oregovomab, Stereotactic Body Radiation Therapy, Therapeutic Conventional Surgery
Procedure · Drug · Other + 2 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 15, 2026, 1:05 AM EDT
Not yet recruiting Phase 2 Interventional

Utilizing Standard of Care Induction Chemotherapy Followed by MR-LINAC Radiotherapy and Surgical Exploration to Improve Resectability Rates in Potentially Resectable Locally Advanced Pancreatic Cancer

NCT07871461
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Induction Chemotherapy - FOLFIRINOX, Induction Chemotherapy - Gemcitabine and Nab-Paclitaxel, MR-LINAC Guided Radiotherapy, Surgical Exploration and Resection
Drug · Radiation · Procedure
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 1:05 AM EDT
Terminated Phase 2 Interventional Results available

Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer

NCT00551759
View directory record Official record
Conditions
Esophageal Cancer
Interventions
5-Fluorouracil, Oxaliplatin, Cetuximab, Docetaxel, Surgery, Radiotherapy
Drug · Procedure · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
109
States / cities
Lewes, Delaware • Newark, Delaware • Aurora, Illinois + 77 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 15, 2026, 1:05 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia

NCT00025038
View directory record Official record
Conditions
Juvenile Myelomonocytic Leukemia
Interventions
tipifarnib, isotretinoin, fludarabine phosphate, cytarabine, radiation therapy, cyclophosphamide, anti-thymocyte globulin, allogeneic bone marrow transplantation, double-unit umbilical cord blood transplantation, umbilical cord blood transplantation, laboratory biomarker analysis
Drug · Radiation · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Oct 15, 2026, 1:05 AM EDT
Terminated Phase 2 Interventional Results available

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

NCT04364048
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Carcinoma
Interventions
Induction Durvalumab, Chemotherapy, Radiation, Consolidation durvalumab
Drug · Radiation
Lead sponsor
Rachel Sanborn
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Chicago, Illinois • Wichita, Kansas • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 15, 2026, 1:05 AM EDT
Completed Phase 2 Interventional Results available

De-Escalation Therapy for Human Papillomavirus Negative Disease

NCT03944915
View directory record Official record
Conditions
Human Papilloma Virus, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, HPV-Related Squamous Cell Carcinoma, HNSCC
Interventions
Carboplatin, Paclitaxel, Nivolumab, Radiation, Hydroxyurea Pill, 5-fluorouracil, Filgrastim Injection, Cisplatin
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 15, 2026, 1:05 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer

NCT00004174
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, cyclophosphamide, paclitaxel, thiotepa, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Northwestern University
Other
Eligibility
Up to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 15, 2026, 1:05 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

NCT05685004
View directory record Official record
Conditions
Glioblastoma Multiforme of Brain
Interventions
TVI-Brain-1, Standard of Care, Radiotherapy, Temozolomide
Biological · Procedure · Radiation + 1 more
Lead sponsor
TVAX Biomedical
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
8
States / cities
Tucson, Arizona • Los Angeles, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 15, 2026, 1:05 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery

NCT00005838
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
shark cartilage extract AE-941, placebo, cisplatin, vinorelbine tartrate, carboplatin, paclitaxel, radiation therapy
Drug · Other · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 15, 2026, 1:05 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma

NCT00006233
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 30, 2011 · Synced Oct 15, 2026, 1:05 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

NCT04866017
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Tislelizumab, Durvalumab, Ociperlimab, Chemotherapy, Radiotherapy
Drug · Radiation
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bolivar, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 15, 2026, 1:05 AM EDT
Active, not recruiting Phase 3 Interventional

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

NCT03257033
View directory record Official record
Conditions
Locally Advanced Pancreatic Cancer
Interventions
Gemcitabine, nab-paclitaxel, RenovoCath
Drug · Device
Lead sponsor
RenovoRx
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
26
States / cities
Loma Linda, California • Sacramento, California • Washington D.C., District of Columbia + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 15, 2026, 1:05 AM EDT
Not listed No phase listed Observational

ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial

NCT02016807
View directory record Official record
Conditions
Oral Mucositis, Nausea, Vomiting, Diarrhea
Interventions
ProThelial
Device
Lead sponsor
Ashley Downs Bioscience
Industry
Eligibility
18 Years to 95 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Foster, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 20, 2013 · Synced Oct 15, 2026, 1:05 AM EDT
Completed Phase 2 Interventional

Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2

NCT00003992
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
44
States / cities
Palo Alto, California • Stanford, California • Denver, Colorado + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 15, 2026, 1:05 AM EDT
Recruiting Not applicable Interventional

Implementing the NYU Electronic Patient Visit Assessment (ePVA) for Head and Neck Cancer In Rural and Urban Populations

NCT06030011
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
NYU Electronic Patient Visit Assessment (ePVA), Usual Care
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Kansas City, Kansas • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 15, 2026, 1:05 AM EDT
Completed Phase 2 Interventional Results available

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

NCT00553098
View directory record Official record
Conditions
Immunodeficiency Syndrome, Non-Cancer Diagnosis
Interventions
Alemtuzumab, Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Total-Body Irradiation
Biological · Procedure · Drug + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 54 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
6
States / cities
Oakland, California • Cleveland, Ohio • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 15, 2026, 1:05 AM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00006012
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
Interventions
filgrastim, amifostine trihydrate, cisplatin, etoposide, paclitaxel, topotecan hydrochloride, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
84
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 51 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 15, 2026, 1:05 AM EDT
Recruiting Phase 2 Interventional

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

NCT04302025
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Alectinib, Entrectinib, Vemurafenib, Cobimetinib, Pralsetinib, Atezolizumab, SBRT, Resection, Chemotherapy, Divarasib
Drug · Procedure
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
38
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 1:05 AM EDT
Completed Phase 2 Interventional

Carboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer

NCT00449020
View directory record Official record
Conditions
Lung Cancer
Interventions
Carboplatin, Docetaxel, irinotecan hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 15, 2026, 1:05 AM EDT
Completed Phase 2 Interventional Results available

Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma

NCT01360593
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Capecitabine, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
David A. Clump, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 15, 2026, 1:05 AM EDT